vTv Therapeutics Inc. (NASDAQ:VTVT) has earned an average rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $16.00.
VTVT has been the subject of several recent research reports. Citigroup reissued an “add” rating on shares of vTv Therapeutics in a research report on Wednesday, November 8th. Zacks Investment Research raised vTv Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Thursday, August 24th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price target on shares of vTv Therapeutics in a research report on Friday, November 3rd.
vTv Therapeutics (VTVT) opened at $4.20 on Friday. vTv Therapeutics has a 1 year low of $3.57 and a 1 year high of $8.09.
ILLEGAL ACTIVITY NOTICE: “vTv Therapeutics Inc. (VTVT) Given Consensus Recommendation of “Buy” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/03/vtv-therapeutics-inc-vtvt-given-consensus-recommendation-of-buy-by-analysts-2.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.